Table 2

HSCT indications in SCD (ebmt.org/Contents/Resources/Library/EBMTESHhandbook)

One of:Neurological deficit due to stroke or subarachnoid haemorrhage
Recurrent acute chest syndrome not responding to 6-month course of hydroxycarbamide
Recurrent vaso-occlusive crises not responding to 6-month course of hydroxycarbamide
AND<16 years
ANDHLA-identical matched related donor available
Candidates who may be considered for HSCT in special circumstances:▸ Problems relating to future medical care e.g. unavailability of adequately screened blood products
▸ SCD relapsing after previous HSCT
▸ Transfusion-dependent S/β0 thalassaemia
▸ Adults aged 17–35 years (as part of clinical trial)
  • HLA, human leukocyte antigen; HSCT, haemopoietic stem cell transplant; SCD, sickle cell disease.